Objective: To determine the tolerance of increasing dosages of an incompletely hydrolysed and/or incompletely absorbed food dextrin coming from wheat starch, NUTRIOSE s FB, at daily levels of 10 and 15 g up to 60 and 80 g, respectively. Design: A randomized, double-blind, multiple dose, placebo-controlled, combined crossover and parallel trial. 
FB is a food dextrin obtained from wheat starch. In contrast to maltodextrin, NUTRIOSE s FB is incompletely hydrolysed and incompletely absorbed in the small intestine. The incomplete hydrolysis and absorption are due to many a-1,6 linkages and the presence of nondigestible glucoside linkages (e.g. a-1,2 and a-1,3), like present in dietary fibres. In an in vivo experiment, 10 nonadapted rats were administered a single dose of 1 g of NUTRIOSE s FB per kg body weight. The 48-h faeces collection after consumption of NUTRIOSE s FB for NUTRIOSE s FB residue determination revealed that about 85% of the product is resistant to enzymatic glucidolytic degradation. These results were in accordance with in vitro experiments from which the same results were observed (unpublished results). Therefore, NUTRIOSE s FB could be considered as a soluble fibre. Some soluble dietary fibres induce intestinal discomfort due to the increased water content related to the osmotic power of these molecules and due to the production of gases.
Compared to other oligosaccharides, NUTRIOSE
s FB may show better tolerance, as it is partly digested and absorbed in the small intestine and about one-fifth of NUTRIOSE s FB is excreted in rat faeces. With increasing dosages supplied, rats excreted more NUTRIOSE s FB (internal data). Like soluble dietary fibre, nondigestible carbohydrates have functional effects such as promotion of a healthy gastrointestinal tract. Other actions of dietary fibre (soluble and insoluble) are related to energy intake. After fibre intake, flattening of blood levels of insulin and glucose has been reported, resulting in a decreased appetite (Albrink, 1978; Hamilton & Anderson, 1992; Rössner, 1992) and less food consumption. However, before the functionality of NUTRIOSE s FB can be established, the tolerable dose of NUTRIOSE s FB should be established first. The aim of this study was to assess the tolerance threshold of NUTRIOSE s FB in grams per day in human subjects used to the compound. However, tolerance and especially the turning point of acceptable to unacceptable intestinal discomfort are very subjective. Therefore, an 'acceptable dose' is hard to evaluate (Roberfroid & Slavin, 2000) , and this was done by a double-blind placebo-controlled food challenge. Tolerance, dietary habits and effects of different dosages of NUTRIOSE s FB on hunger and satiety feelings were estimated by questionnaires and visual analogue rating scales. Fermentation of NUTRIOSE s FB was confirmed with the breath H 2 excretion test.
Subjects and methods

Subjects
A total of 26 men aged between 20 and 45 y were recruited from the pool of volunteers of TNO Nutrition and Food Research and by advertisements in local newspapers. After signing the informed consent forms, health was assessed at pre-study screening. This included a medical history, physical examination and routine laboratory tests on blood and urine sampled during the pre-study screening. A lactulose breath test was done to exclude those subjects who appeared to have no hydrogen-producing microflora. For this test, subjects came to the institute after an overnight fast and ingested a drink with 10 g lactulose with a standard breakfast. Breath samples were taken before and at 30 min intervals after the lactulose drink for 240 min after lactulose consumption. An increase of 10 ppm was used as inclusion criterion. One volunteer did not show hydrogen responses to lactulose and was excluded from the study. Three men failed the pre-study screening laboratory test and one subject was not suitable. Thus, 21 healthy men were included in this study, including one who could substitute a subject who would refuse to start the study. Of the 20 men who participated in the study, the age ranged between 20 and 44 y (mean 31.779.1 y) and BMI ranged between 20.1 and 29.5 kg/m 2 (mean 24.572.9 kg/m 2 ). From 1 month before the start of the study, none of the subjects had used antibiotics or laxatives. The study was approved by the Medical Ethics Committee of TNO, and conducted according to the ICH Guideline for Good Clinical Practice.
Study substances NUTRIOSE
s FB (Roquette Frères, France) is a purified glucose polymer processed by heating wheat starch at high temperature, adjusted to a low moisture level in the presence of an acid catalyst. The dextrin obtained is then purified with activated carbon and demineralized by exchange resins. Afterwards, the product is chromatographed and the highmolecular-weight fraction is retained and spray-dried.
Maltodextrin (Glucidex s 6) was selected as placebo, as NUTRIOSE s FB is also originally a dextrin from wheat. The exact composition is given in Table 1 .
The study substances were supplied as a powder. To abolish any difference in colour and taste between the two study substances, both products were caramel-coloured and aspartame-sweetened. In a small pilot study, a sensory panel found no differences in taste, colour or mouth-feel when the products were added to grape juice or fruit yoghurt. Therefore, when ingested at the institute, the study substances were added to these food products.
Design
The study was designed as a randomized, placebo-controlled, multiple-dose, double-blind trial, with a crossover part for treatment and a parallel part for dosage or treatment variation. With this design, it is possible to examine the main question, concerning tolerability of high dosages after two different adaptation periods (10-30-60 and 15-45-80 g) in the most efficient way. The duration of the study was 8 weeks and consisted of four periods: a run-in period of 1 week followed by two treatment periods of 3 weeks each, which were separated by a wash-out period of 1 week. During the run-in period (day À7 to À1), the subjects received a placebo. A treatment period consisted of three periods of 7 days each (days 1-22 and days 29-50), during which the dose of the study substances increased, enabling the subjects to slowly adapt to the high supplementation dose. Figure 1 .
Each volunteer was given an exclusion list of fibre-rich foods and foods containing pre-and probiotics to be avoided during the study period (day À7 up to and including day 49). Each seventh day after a standard breakfast with or without the study substance, the subjects filled in a questionnaire on gastrointestinal symptoms, compliance and food habits.
Test days
On days À1, 21 and 49, after the first questionnaire, a food frequency questionnaire (FFQ) was filled in. The FFQ was developed in Food Frequency Expert (FOFREX), a computerized system with data from the second Dutch national food consumption survey of 1992 (National Education Board, 1992) and a predefined question matrix. Changes in dietary intake (total energy, protein, fat, carbohydrates, alcohol, fibre) over the past 3 weeks were evaluated.
On the evening before day 7 and day 35, subjects ate a standardized dinner and an evening snack to avoid interference with the breath H 2 excretion test. The following day, breath samples were taken. With breakfast (t ¼ 0 min), at t ¼ 120 min, and during lunch (t ¼ 240 min), a total of three quarters of the daily dose of study substance were ingested.
The diet during the 480-min H 2 excretion test was standardized. Next to the breath samples, the subjects were asked to fill in visual analogue rating scales (VARS) on hunger and satiety feelings and food preferences throughout the day. The standard breakfast consumed during days 7 and 35 consisted of two white rolls spread with low-fat margarine. 15 g of jam; 20 g of cheese; 150 g of skimmed fruit yoghurt; one glass of skimmed milk; one mug of tea; and a quarter of the study substance (energy: 2490 kJ; protein: 15.7% of total energy; fat: 28.2%; carbohydrates: 56.0%; and 2.9 g of dietary fibre). In the morning, the subjects further consumed: a piece of cake with a cup of coffee and one glass of orange juice with study product. Standard lunch during the test day was: two slices of corn bread, one biscuit rusk, low-fat margarine, luncheon meat, chicken meat, fruit coloured sprinkles, skimmed milk, cup of tea and study product. In the afternoon, two cups of tea, one apple and a small chocolate bar prepared with milk (Milky Way s ) were eaten.
Materials and analyses
Questionnaire on well-being, compliance and food habits. Using a questionnaire, the frequency and severity of gastrointestinal symptoms, compliance and dietary habits were evaluated on each seventh day of treatment. The questions concerned either the past 6 days or the past 24 h on a particular dose of the study substance. Feelings of severity of abdominal symptoms were rated by VARS as well. The following symptoms were evaluated: number of stools, texture of stools, flatulence, borborygmus, belching, nausea feelings, bloating, vomiting and stomach cramps or stomach pain. If a symptom was not present, the severity of the particular complaint was not taken into account. The answers to questions on frequency of a symptom during the past 6 days were categorized by frequency. The other data on gastrointestinal symptoms concerned continuous data. Figure 1 Study design. Each dose of each 3-week treatment was given for 7 days, followed by a wash-out period of 7 days. N ¼ NUTRIOSE s FB; P ¼ Placebo (Glucidex s 6).
Diarrhoea was defined as 'defecation with volume increase, a more liquid texture of the faeces (Kumar & Clark, 1994 ) and a frequency of 43 times a day'.
Dietary habits evaluated were (1) frequency of having appetite for breakfast, lunch, dinner, a snack, something sweet or something savoury during the past 6 days; (2) times persuading oneself to have breakfast, lunch or dinner during the past 6 days; (3) frequency of looking forward to having the next meal during the past 6 days; (4) frequency of having appetite for lunch or dinner after having eaten a snack during the past 6 days; (5) frequency of eating something or taking a snack during the past 24 h; and (6) preference for (non)-fibre products, something savoury or something sweet during the past 24 h. All data on dietary habits were categorical.
Breath hydrogen excretion. The breath hydrogen excretion test was only carried out for the 10 and 15 g/day doses of NUTRIOSE s FB and maltodextrin. For the breath H 2 tests, breath samples were taken just before (t ¼ 0), at 60 min and every 30 min from 120 to 480 min after a standard breakfast with the study substance. The breath H 2 tests were performed with a Lactoscreen H 2 breath tester or a LactoMeter (TEFA-Portanje, Woerden, Netherlands). Subjects were instructed to breathe out as deeply as possible to obtain alveolar air. The subjects exhaled directly into the apparatus via a mouthpiece. Within the same subject, all measurements were done with the same apparatus. The interval between ingestion of NUTRIOSE s FB and the initial sustained rise in breath hydrogen Z10 ppm from basal concentrations (the lowest previous concentration) represents the orocaecal transit time (OCTT) (Jorge et al, 1994; Rumessen and Gudmand-Høyer, 1998 ).
Visual analogue rating scales (VARS). Hunger and satiety were measured just before breakfast (time point 0) and at 30, 60, 90, 120, 150, 180, 240 (just before lunch), 270 and 480 min. Feelings of hunger and satiety were rated by means of a slash on five 10 cm VARS. The VARS lines were labelled (1) appetite for a meal; (2) appetite for something sweet; (3) appetite for something savoury; (4) satiety (fullness) and (5) feeble/weak with hunger (Hulshof, 1994) . The lines were anchored at the extremes with hardly or enormous urge for the specific item.
Statistics
The number of subjects per group (n ¼ 10) was based on other studies examining breath hydrogen excretion performed with this number of subjects or even less (Rumessen and Gudmand-Høyer, 1998 ; n ¼ 10) and studies about hunger and satiety. Other studies investigating the tolerance of dietary fibre were done with a similar number of subjects (Ruskone-Fourmestraux et al, 2003 (n ¼ 12) ; Sinau et al, 2002 (n ¼ 9)).
The categorical data, which include part of the gastrointestinal complaints and the answers about food habits, were statistically analysed with the Wilcoxon rank test. When more categories were present, the data were reduced to three categories: increase, decrease and no difference. The increases and decreases were statistically analysed by using the sign test and a Fisher exact test. The Fisher exact test was used to test on carry-over and the sign test to test on treatment effect.
The continuous data obtained were statistically analysed by ANOVA. For the breath H 2 excretion test, the area under the curve (AUC), the maximum breath H 2 concentration (C max ) and the time to reach the maximum (t max ) were analysed. The AUC was the product of the total area above and below the value at t ¼ 0.
Ratings of hunger and satiety were converted into scores from 1 (weak) to 10 (strong). To enable the overall comparison of the effects of six different dosages on appetite feelings, the AUC was taken as the dependent parameter. To get an impression of timing, the maximum score (C max ) and the time of this maximum (t max ) were also statistically analysed. Besides comparisons within each dose, ANOVA for repeated measurements was used to compare total dose sequences (10-60 or 15-80 g/day) between treatments.
Most statistical analyses were carried out with the SAS statistical package (SAS Institute, version 6.12, 1989) . The ANOVA for repeated measurements was carried out with the Genstat statistical package (Genstat 5 Committee, 1994) .
If the parameters did not have a symmetrical distribution, natural logarithms of these data were used in the statistical tests. All continuous data on gastrointestinal complaints had a symmetrical distribution. However, when these data were corrected for the control treatment (parallel design), the symmetrical distribution of some parameters disappeared. These parameters include frequency of belching, bloating, borborygmus in stomach, stomach cramps and severity of flatulence during the past 24 h. For these parameters, no logarithmic transformation could be carried out as these parameters include many zero or negative values. Therefore, not all dosages of study substances could be compared. In addition, most parameters on hunger and satiety did not have a symmetrical distribution. Since there were many negative or zero values, a logarithmic transformation was not meaningful. Therefore, an alternative statistical test was applied, that is, ANOVA on rank number (Conover, 1999) .
In all statistical tests performed, the null hypothesis (no treatment effect) was rejected at the 0.05 level of probability.
Results
Questionnaire on well-being, compliance and food habits On the basis of the diary report and questionnaires, compliance was estimated at 99.6%, which was considered very good. Only when the gastrointestinal symptoms differed between treatments, the data are shown. Table 2 shows that flatulence occurred significantly more frequently FB (Po0.05). In addition, the subjects experienced flatulence as more serious over the last 6 days on 60 and 80 g/day of NUTRIOSE s FB (Po0.05). During the last 24 h, that is, days 6-7 on 60 and 80 g/day of NUTRIOSE s FB, the frequency of flatulence was still higher than during the control treatment (Po0.05). Also, the severity of flatulence was still greater during the last 24 h on 80 g/day of NUTRIOSE s FB than in the control treatment. The frequency of defecation during the last 24 h of treatment with 60 g/day of NUTRIOSE s FB was lower than that for the control treatment. During the last 24 h on 15 g/ day of NUTRIOSE s FB, the subjects reported that their faeces were thicker than during the last 24 h on 15 g/day of the placebo. The effect of higher dosages of NUTRIOSE s FB on the frequency of defecation and thickness of faeces was not consistent. A daily dose of 80 g NUTRIOSE s FB did not lead to a lower frequency of defecation. Dosages higher than 15 g/ day of NUTRIOSE s FB did not result in thicker faeces. Compared with the placebo, none of the dosages of NUTRIOSE s FB increased the occurrence of diarrhoea, defined as 'defecation with a more liquid consistency of the faeces and a frequency of three or more times a day'.
The subjects reported an increased frequency of bloating during the last 24 h on 80 g/day of NUTRIOSE s FB compared to the control treatment. Belching during the last 24 h tended to increase on 30 (P ¼ 0.09), 60 and 80 g/day of NUTRIOSE s FB (P ¼ 0.06; see Figure 2 ). For the following parameters, the ANOVA for repeated measurements showed a significant interaction: the parameters 'severity of flatulence during the last 6 days' and 'frequency of flatulence during the last 24 h' during both dosage sequences. During the dosage sequence (10-30-60 g), the parameter 'frequency of belching during the last 24 h' (Figure 2) , and during the dosage sequence 15-45-80 g 'severity of flatulence during the last 24 h', differed in course over time. A significant interaction showed that the earlier dose of NUTRIOSE s FB given for 7 days differently affected the outcome of the particular parameter on day 7, 14 or 21 relative to placebo. 
Tolerance of NUTRIOSE
s No significant differences between treatments were present for any of the food habit variables. Average dietary intake as measured by the FFQ and calculated before and after each dosage sequence did not change during the study. Figures 3 and 4 show the average rating on 'feeble or weak with hunger' and 'satiety (fullness)' on day 7 of treatment with 10 or 15 g of the study substance. Only the AUC of the rating on 'feeble or weak with hunger' was lower on day 7 of the treatment with 15 g/day of NUTRIOSE s FB compared to 15 g/day of the placebo (P ¼ 0.04). No other significant differences were found.
Hunger and satiety feelings
Breath hydrogen excretion
The mean OCTT after 7 days on 10 g/day of NUTRIOSE s FB was 267 min (CV 38%). After 7 days on 15 g/day of NUTRIOSE s FB the OCTT was 193 min (CV 48%). Figures 5  and 6 show the mean breath H 2 excretion on day 7 of the 10 or 15 g study substance. Although all curves show an increase as compared with the basal measurement (containing the placebo), no statistical difference in AUC, t max and C max were found among the different treatments.
Discussion
Tolerance Fermentation of carbohydrates by the intestinal microflora results in the production of short-chain fatty acids, lactate and gases. Production of gas by the intestinal flora may result in increased pressure in the colon. This in turn will result in bloating, pain and flatulence (Hartemink & Rombouts, 1997) . When the fermentation capacity of the colonic bacteria is exceeded, diarrhoea may develop (Carabin & Figure 4 Response on feelings of satiety (fullness) on day 07. The data concern only two dose comparisons. Within each of the 10 subject ratings during 10 g/day of placebo and 10 g/day of NUTRIOSE s FB were compared. Within each of the 10 other subject ratings during 15 g/day of placebo and 15 g/day of NUTRIOSE s FB were compared. , 1999) . Thus, flatulence and diarrhoea are two potential problems that may develop when the diet is too rich in fermentable carbohydrates. Since the amount of fermentable carbohydrate is critical in avoiding problems with intolerance (Stone-Dorshow & Levitt, 1987) , in this study, the threshold of gastrointestinal discomfort due to NUTRIOSE s FB was determined. Standard maltodextrin was used as placebo as reported earlier (Van Munster et al, 1994) . During 6 days on 30, 60 or 80 g of NUTRIOSE s FB per day, the frequency of flatulence was higher than with the control treatment (same dose of maltodextrin). The subjects only experienced flatulence as more serious when the daily dose of NUTRIOSE s FB was 60 g or higher, and not for the 30 g of NUTRIOSE s FB daily. Although bloating occurred more frequently during the week on 80 g of NUTRIOSE s FB per day, the subjects did not experience this complaint as more serious. The frequency, but not severity, of borborygmus increased as well compared with the placebo. NUTRIOSE s FB up to a dose of 45 g/day was well tolerated. Above 45 g/day, the increase in flatulence may become more unpleasant for consumers. No diarrhoea occurred even at the highest level of NUTRIOSE s FB (80 g/day). Therefore, the threshold dose above which diarrhoea may occur is more than 80 g/day of NUTRIOSE s FB. According to Bouhnik et al (1999) , the optimal and welltolerated dose of fructo-oligosaccharides in healthy volunteers on their usual diet is 10 g/day. The first symptoms of intolerance (excessive flatulence) were found above 30 g of fructo-oligosaccharides per day (Briet et al, 1995) . Abdominal complaints occurred after a single dose of short-or longchain fructans of more than 20 g (Rumessen and GudmandHøyer, 1998) . In case of transgalacto-oligosaccharides, Sako et al (1999) estimated that the critical amount is 0.3-0.4 g per kg body weight, or about 20 g per day. Different structures of the fermentable carbohydrate and/or the experimental conditions (habituation due to increasing dosage and spread over the day) may explain the higher tolerable dose of 45 g NUTRIOSE s FB per day. Smaller molecules with a lower degree of polymerization (DP) have a higher osmotic colonic pressure. More slowly fermentable compounds are tolerated more readily than rapidly fermented ones (Carabin & Flamm, 1999) . Rumessen and Gudmand-Høyer (1998) found in healthy subjects (n ¼ 10, 18-25 y) that complaints of intestinal discomfort were milder for long-chain fructans (42% with DP 421) than for short-chain fructans (DP 3) and lactulose at 20 g/day. The higher degree of polymerization of NUTRIOSE s FB (DP 18) than for other nondigestible carbohydrates, and hence lower osmotic pressure and slower fermentation, may thus explain the high threshold of intestinal discomfort and welltolerance of a high supplementation dose.
Tolerance of NUTRIOSE
Furthermore, in this study, the subjects ingested the dose throughout the day, which is known to increase tolerance (Carabin & Flamm, 1999) . Moreover, the dose of NUTRIO-SE s FB increased during a period of 21 days with increasing dose (10-30-60 or 15-45-80 g ) and each dose of NUTRIO-SE s FB was given for 6 full days (at day 7 after the measurements, no products were consumed). This slow adaptation and habituation to NUTRIOSE s FB may have further increased tolerance, which agrees with the findings of Hertzler and Savaiano (1996) on lactose in lactose maldigesters. In our study, the subjects on a daily intake of 60 g of NUTRIOSE s FB for 6 days experienced flatulence as more severe than those during the control treatment. This was no longer the case for the last 24 h, also suggesting an adaptation to NUTRIOSE s FB. In contrast, for 80 g/day of NUTRIOSE s FB, the more severe flatulence was still present when subjects were asked after the last 24 h. A dose of 80 g/ day may therefore be too high to attenuate severe flatulence, or a period of adaptation longer than 6 days may be necessary.
Breath hydrogen excretion
In our present study, fermentation was studied by the breath hydrogen excretion test. This test was carried out on the last day of 10 or 15 g/day of NUTRIOSE s FB or placebo treatment. As compared with baseline, that is, breath hydrogen excretion before breakfast, all curves significantly increased. However, no difference in AUC was found among treatments. Explanations for the absence of a significant difference in AUC attributable to NUTRIOSE s FB may be the amount of dietary fibre consumed with the standard breakfast (2.9 g), the split and thus relatively small dose of NUTRIOSE s FB (2.5 or 3.0 g) with each meal, or the large variance in measurement data.
First, the breakfast consumed with the first quarter of the dosage of NUTRIOSE s FB or maltodextrin contained already 2.9 g of dietary fibre. This may have resulted in a higher basal breath hydrogen excretion level, which interferes with the effect of NUTRIOSE s FB. Second, like in our study, Van Dokkum et al (1999) spread the dose of 15 g/day of fructo-oligosaccharides over the day and did not find a difference in AUC between the treatment and control (no nondigestible oligosaccharides). Hydrogen production increased nonlinearly with an increasing dose of fructans (up to 30 g: Rumessen & Gudmand-Høyer, 1998) . In both our study and the study of Van Dokkum et al (1999) , a smaller amount of carbohydrates was available for fermentation due to the spread of the dose over the day. In our study, the volunteers ingested three quarters of the 10 or 15 g/day of NUTRIOSE s FB at breakfast, at t ¼ 120 and at t ¼ 240 min. From rat experiments, we know that ca. 45% of NUTRIO-SE s FB is absorbed or excreted into faeces, while in man 10% is excreted with the faeces and consequently is not available for fermentation. Therefore, the amount of NUTRIOSE s FB studied may have been too small to find a significant difference in AUC as compared with maltodextrin.
Finally, in our study, a wide within-subject variance of the AUC was found, which is supported by other research (Hartemink & Rombouts, 1997; Koetse et al, 2000) . Individual differences in breath H 2 AUC between duplicate test Tolerance of NUTRIOSE s days ranged from 4 to 39% (Gelissen et al, 1994) . Both the between-and within-subject variances depend on the substrate and are higher for polysaccharides than for oligosaccharides (Hartemink & Rombouts, 1997) . In our study, the mean AUC for the treatment with 15 g/day of NUTRIOSE s FB was three times the AUC for the control treatment, but the difference was not significant (P ¼ 0.3). With a power of 80%, we would have been able to detect a six-fold higher AUC for NUTRIOSE s FB (Po0.05; two-sided). Nevertheless, in our study, the clear rise in breath hydrogen excretion relative to baseline confirms the fermentation of NUTRIOSE s FB.
Food habits and satiety
In our study, an increasing dose of NUTRIOSE s FB did not affect food habits as compared with the placebo. Feelings of appetite were measured on day 7 of treatment with 10 or 15 g/day of NUTRIOSE s FB or placebo. The subjects recorded less 'hunger' during the daily intake of 15 g NUTRIOSE s FB compared with placebo. Although the term 'hunger' seems opposite to satiety, the state that occurs after the meal and inhibits further eating, we found no higher satiety scores. This might be due to a different interpretation of satiety.
The differences in baseline value as seen in Figure 3 could be a result of the differences in habituated breakfast and dinner intake the previous day. During the test day, these meals were controlled and contained more or less energy than their habitual breakfast or dinner.
Like NUTRIOSE s FB, consumption of 30 g/day of resistant starch for 1 week had little influence on appetite and food consumption in healthy young men (De Roos et al, 1995) . However, these subjects were allowed to eat and drink ad libitum. It could be expected that the subjects adjusted their energy intake to the supplement, so their habitual pattern of appetite dimensions did not change (de Roos et al, 1995) . In our study, we strictly controlled dietary intake over the test day.
From the literature, satiating effects of fermentable fibre are known; however, in most of the controlled studies described, next to fibre intake the energy intake from the controlled diet was varied. Duncan et al (1983) found the same levels of satiety despite a 50% lower energy intake in the high-fibre diet. In contrast to a high energy intake (6 MJ), a daily intake of 20 g of guar gum to a diet with 4 MJ reduced hunger scores and increased the satiety scores of obese subjects (Pasman et al, 1997) . Consequently, fibre supplementation may be of interest for the possibility to maintain a reduced energy intake in order to prevent weight gain (Pasman, 1998) . In our study, only a small difference in energy content was attributable to the difference in study substance. NUTRIOSE s FB contains about 50% of the energy value of the placebo maltodextrin. Consequently, the daily diet with 10-15 g of NUTRIOSE s FB contained 84-126 kJ less energy, which is only 0.7-1.1% of the daily energy intake of men aged 22-50 y (Dutch Food Consumption Survey, 1998).
To be able to detect a satiating effect of NUTRIOSE s FB, probably we should have further reduced energy intake on the day of measurement, as is examined before (Pasman et al, 1997) . In the long term, fibre supplementation might be effective for weight maintenance or prevention of weight gain (Rolls, 1995) , especially in combination with a low calorie diet (Birketvedt et al, 2000) .
As 30 g of NUTRIOSE s FB resulted in a little more frequent but not more severe flatulence, we conclude that NUTRIO-SE s FB up to a dose of 45 g is well tolerated. Higher dosages (60 and 80 g/day) may result in more flatulence experienced by the subject as more severe than during the control treatment. Duration of the treatment on 60 g/day of NUTRIOSE s FB may lead to colonic adaptation and thus promote tolerance of higher doses of NUTRIOSE s FB. A dose of 80 g/day may be too high to prevent severe flatulence, or prolongation of the adaptation period is needed. Compared with placebo, none of the dosages of NUTRIOSE s FB led to diarrhoea. Besides flatulence, the subjects experienced more bloating during the last 24 h on 80 g/day of NUTRIOSE s
FB.
With the results on flatulence, bloating suggests a higher production of gas, which is weakly confirmed by the breath hydrogen excretion test. Although NUTRIOSE s FB may result in feeling less hungry, more research is needed to confirm a role of NUTRIOSE s FB in hunger and satiety regulation.
